These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The management of hypertension in ischaemic heart disease.
    Author: Hawkins NM, Dunn FG.
    Journal: Curr Opin Cardiol; 2006 Jul; 21(4):273-8. PubMed ID: 16755194.
    Abstract:
    PURPOSE OF REVIEW: Patients with hypertension and coronary artery disease are often inadequately treated. Blood pressure levels remain unacceptably high in about half of such patients. A significant shortfall exists between guidelines and practice in implementing evidence-based drug therapy. RECENT FINDINGS: Recent trials underscore the importance of blood pressure reduction. The purported superiority of specific drug classes, notably angiotensin-converting enzyme inhibitors and beta-blockers, is increasingly debated. Conversely, the benefits of calcium channel blockers are increasingly recognized. Irrespective of differences, all three agents are frequently required to achieve blood pressure targets. Beyond blood pressure reduction, statin therapy is undoubtedly the single most important risk factor intervention. New studies suggest that intensive lipid lowering and greater reductions in low-density lipoprotein cholesterol will further reduce major cardiovascular events. Finally, the impact of smoking cessation, exercise, and diet is often underestimated. SUMMARY: The prognosis for patients is critically dependent on reducing global cardiovascular risk by addressing all modifiable risk factors. The cornerstone of treatment remains blood pressure reduction, using agents with both antihypertensive and antianginal properties.
    [Abstract] [Full Text] [Related] [New Search]